Skip to main content

Table 1 Description of the study populations

From: The data management of a phase III efficacy trial of an 11-valent pneumococcal conjugate vaccine and related satellite studies conducted in the Philippines

Study

Study areas

Age of population

Study group

Phase 3 RCT study

   

Efficacy study

6 study municipalities

Children aged 6 weeks to 6 months and monitored until 2 years old

RCT

Nested study

3 predefined health centres included Dao (Tagbilaran), Danao and main health centre in Panglao

Children aged 6 weeks to 6 months and monitored until 2 years old

RCT

Hospitalization in BRH

6 study municipalities

Children less than 5 years old

RCT, EPI and Epi grey

Hospitalization in the private hospital and OPD consultation in BRH

6 study municipalities

Children less than 2 years old

RCT, EPI and Epi grey

Satellite studies

   

Herd immunity

6 study municipalities

Children enrolled in the efficacy study w/elder sibling enrolled in the efficacy study

RCT

Cost effectiveness(hospitalization for pneumonia, sepsis, or meningitis at BRH and three private hospitals)

6 study municipalities

Children enrolled in the efficacy study from 6 weeks to 23 months old and admitted to hospital or consulted the OPD

RCT

Acute otitis media(hospitalization or consultation at BRH for pneumonia, sepsis, or meningitis)

6 study municipalities

Children less than 5 years old diagnosed with pneumonia and/or AOM

RCT, EPI and Epi grey

Wheezing(hospitalization or consultation at BRH for pneumonia, sepsis, or meningitis)

6 study municipalities

Children less than 5 years old

RCT, EPI and Epi grey

Pertussis(hospitalization or consultation at BRH for pneumonia, sepsis, or meningitis)

6 study municipalities

Children less than 13 years old

RCT, EPI and Epi grey, children not necessary enrolled in RCT